Tech Company Financing Transactions
Revance Therapeutics Funding Round
Revance Therapeutics, based in Nashville, secured $5.9 million from private investors.
Transaction Overview
Company Name
Announced On
9/17/2012
Transaction Type
Venture Equity
Amount
$5,919,191
Round
Series E
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing-amended.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1222 Demonbreun St. 2000
Nashville, TN 37203
USA
Nashville, TN 37203
USA
Phone
Website
Email Address
Overview
Revance (NASDAQ: RVNC) is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance's platform technologies to enhance patient tolerability of botulinum toxin.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Foley
Chief Financial Officer
Tobin Schilke
Chief Operating Officer
Abhay Joshi
VP - Bus. Development
Dustin Sjuts
VP - Human Resources
Justin Ford
Browse more venture capital transactions:
Prev: 9/17/2012: Edge Therapeutics venture capital transaction
Next: 9/17/2012: MetraTech venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs